BetterLife Pharma Inc
Research BetterLife Pharma Inc (NPAU) on Bullrun: market cap EUR 29.19M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNPAU
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 29.19M
- Financial periodQ2 2026
- RevenueCAD 0
- Net income-CAD 609.26K
- Free cash flow-CAD 239.23K
Valuation Snapshot
latest market cap is EUR 29.19M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 1.85M | -CAD 217.61K | n/a | n/a | CAD 7.96K | CAD 1.04M | -CAD 9.46M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 29.19M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About BetterLife Pharma Inc
BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BetterLife Pharma Inc's market cap?
BetterLife Pharma Inc's market capitalization is EUR 29.19M.
What does BetterLife Pharma Inc do?
BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation. The company was formerly known as Pivot Pharmaceuticals Inc.